AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

PARP inhibitors have historically been able to show some tumor progression benefits, but these benefits haven’t always translated into longer patient life spans thanks in part to nasty side effects.

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

Figure 2: Classification of the poly-ADP-ribose-polymerase (PARP) family according to the structural model proposed by Kleine et al.7. To identify the PARP10 residues that are post-translationally ...

PARP kicked off on Feb. 6 with an evening event organized by library media specialist Tara Gonzalez. More than 150 students visited the reading stations led by teachers and parent volunteers.

Idience’s focus on anticancer drugs that could transform patient quality of life is exemplified by its lead asset IDX-1197, a PARP inhibitor that is currently in a phase 1b/2a basket study with ...